Each week on DocWire News, editors bring you the latest in oncology news and cancer research. In case you missed it, here are this week’s top headlines:
- VIDEO: Dr. Carolyn Kay on Identifying HPV+ Patients at Higher Risk for Cervical Cancer
- ASTRO Guideline for EBRT in Liver Cancer: Key Takeaways
- Tailored Strategies Can Up Depression Referrals in Breast Cancer
- Psychological Distress More Likely in Young Adult Cancer Survivors
Keep reading for the breakdown on these top stories.
RELATED: Last Week’s Round-Up: Is Maternal Contraception Related to Pediatric CNS Tumors?
Dr. Carolyn Kay: Identifying High-Risk HPV
Editors sat down with Dr. Carolyn Kay, an OB/GYN physician, about results from the IMPACT trial, which demonstrated that Roche’s CINtec PLUS Cytology, when used as a triage test for high-risk human papillomavirus (HPV), showed significantly higher sensitivity in detecting cervical pre-cancers in HPV-positive women compared to Pap cytology.
“The objective of the study was to compare the diagnostic performance of the biomarker technology to Pap cytology for the triage of high-risk HPV positive results,” said Dr. Kay. “[These data] formed the basis of the FDA approval of our dual biomarker cytology test, commercially known as CINtec PLUS.”
RELATED VIDEO: Women’s Health Expert on the Impact of Unplanned Pregnancy
ASTRO Guideline for EBRT in Liver Cancer
The American Society for Radiation Oncology (ASTRO) released a new guideline regarding external beam radiation therapy (EBRT) for primary liver cancer. This is the first ASTRO guideline regarding primary liver cancers, and it was published in Practical Radiation Oncology.
- EBRT is strongly recommended as:
- a potential first-line treatment in liver-confined hepatocellular carcinoma (HCC) in patients ineligible for curative therapy
- consolidative therapy after incomplete response to previous liver-directed therapies
- a salvage option for local recurrence.
- EBRT is conditionally recommended:
- for patients with liver-confined multifocal or unresectable HCC
- for patients with macrovascular invasion, in sequence with systemic or catheter-based therapies
- as a palliative therapy for symptomatic primary HCC and/or macrovascular tumor thrombi
- as a bridge to transplant or before surgery in selected patients
- as an adjuvant therapy for resected intrahepatic cholangiocarcinoma (IHC) with high-risk features
Tailored Strategies Can Up Depression Referrals in Breast Cancer
For patients with newly diagnosed breast cancer, tailored strategies for implementation of routine depression screening result in a greater proportion of referrals to behavioral care, according to a study published in JAMA.
Researchers examined the effectiveness of an implementation strategy-guided depression screening program in a trial conducted at six medical centers with 1,436 patients diagnosed with new primary breast cancer. The centers were randomly assigned to either tailored implementation strategies (three sites; 744 patients) or education-only (three sites; 692 patients). The program consisted of 9-item Patient Health Questionnaire screening and algorithm-based scoring and referral to behavioral health services; at tailored intervention sites, clinical teams received program education, audit, and feedback of performance data and implementation facilitation.
The researchers found that 7.9% and 0.1% of patients at tailored sites and education-only sites, respectively, were referred. Referrals to a behavioral health clinician were completed by 44 of 59 (75%) and one of one patient at the intervention and education-only sites, respectively. Patients at tailored sites had significantly fewer outpatient visits in medical oncology; no differences were seen in utilization of primary care, urgent care, or emergency department visits.
Want to see more oncology news?
Check out last week’s Round-Up, and be sure to keep up with the latest oncology news and cancer research here on DocWire, updated daily!